Oncothyreon (ONTY) – Press Releases
-
Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics (NASDAQ: CASC)
-
Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO
-
Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update
-
Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016
-
Oncothyreon Appoints Scott D. Myers Chief Executive Officer
-
Oncothyreon Reports Full Year and Fourth Quarter 2015 Financial Results & Provides Corporate Update
-
Oncothyreon to Present at Cowen and Company 36th Annual Health Care Conference
-
Oncothyreon Announces First Patient Dosed in Randomized Phase 2 ONT-380 Combination Trial in Patients with HER2-Positive Breast Cancer
-
Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. as Interim CEO and Expands Board With Additions of Mark Lampert and Gwen Fyfe, M.D.
-
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
-
Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer Symposium
-
Oncothyreon Announces Webcast to Review Updated Clinical Data on ONT-380 in HER2-Positive Breast Cancer Patients
-
Oncothyreon to Present Updated Data on ONT-380 for the Treatment of HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium
-
Oncothyreon Reports Third Quarter 2015 Financial Results
-
Oncothyreon Announces Third Quarter 2015 Financial Results Conference Call
-
Oncothyreon to Present at Rodman & Renshaw Annual Global Investment Conference
-
Oncothyreon to Present at Rodman & Renshaw Annual Global Investment Conference
-
Oncothyreon Reports Second Quarter 2015 Financial Results
-
Oncothyreon Reports Second Quarter 2015 Financial Results
-
Oncothyreon Announces Second Quarter 2015 Financial Results Conference Call
-
Oncothyreon Announces Second Quarter 2015 Financial Results Conference Call
-
Rodman & Renshaw 2015 Annual Global Investment Conference to be held in New York from September 8 to 10, 2015
-
Oncothyreon Announces Presentation of Positive ONT-380 Data in HER2-Positive Breast Cancer at ASCO Annual Meeting and Updates Development Plan
-
Oncothyreon Announces Presentation of Positive ONT-380 Data in HER2-Positive Breast Cancer at ASCO Annual Meeting and Updates Development Plan
-
Oncothyreon to Present at Jefferies 2015 Healthcare Conference
-
Oncothyreon to Present at Jefferies 2015 Healthcare Conference
-
Oncothyreon Reports First Quarter 2015 Financial Results
-
Oncothyreon Announces First Quarter 2015 Financial Results Conference Call
-
Oncothyreon Announces First Quarter 2015 Financial Results Conference Call
-
Oncothyreon Reports Full Year and Fourth Quarter 2014 Financial Results
-
Oncothyreon Reports Full Year and Fourth Quarter 2014 Financial Results
-
Oncothyreon Prices $22 Million Concurrent Public Offerings of Common Stock and Preferred Stock
-
Oncothyreon Announces Proposed Public Offerings
-
Oncothyreon Announces Presentation of Positive ONT-380 Data at San Antonio Breast Cancer Symposium
-
Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380
-
Annual Changes to the NASDAQ Biotechnology Index
Back to ONTY Stock Lookup